STOCK TITAN
  1. Home
  2. News
  3. XAIR

Beyond Air Inc - XAIR STOCK NEWS

IMPACT
SENTIMENT
XAIR : Nasdaq
Beyond Air® Receives Grant for Up to $2.17 million from the Cystic Fibrosis Foundation to Advance the Clinical Development of Inhaled Nitric Oxide to Treat Nontuberculous Mycobacteria Pulmonary Disease
clinical trial
IMPACT
SENTIMENT
XAIR : Nasdaq
Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2021 and Provides Business Update
earnings
IMPACT
SENTIMENT
XAIR : Nasdaq
Beyond Air® Schedules Third Fiscal Quarter 2021 Financial Results Conference Call and Webcast
earnings
IMPACT
SENTIMENT
XAIR : Nasdaq
Beyond Air® Initiates Patient Screening for LungFit™ GO Pilot Study for At-Home, Self-Administration of Inhaled Nitric Oxide in Nontuberculous Mycobacteria Lung Disease
IMPACT
SENTIMENT
XAIR : Nasdaq
Beyond Air® to Participate in the 32nd Annual Piper Sandler Healthcare Conference from December 1-3, 2020
conferences
IMPACT
SENTIMENT
XAIR : Nasdaq
Beyond Air® Reports Financial Results for Second Quarter of Fiscal Year 2021 and Provides Business Update
earnings
IMPACT
SENTIMENT
XAIR : Nasdaq
Beyond Air® Submits Premarket Approval Application to FDA for LungFit™ PH to Treat Persistent Pulmonary Hypertension of the Newborn
IMPACT
SENTIMENT
XAIR : Nasdaq
Beyond Air® Schedules Second Fiscal Quarter 2021 Financial Results Conference Call and Webcast
earnings
IMPACT
SENTIMENT
XAIR : Nasdaq
Beyond Air® Approved to Initiate Clinical Study at 150 ppm Nitric Oxide with LungFit™ for the Treatment of Acute Viral Pneumonia Including COVID-19
clinical trial covid-19
IMPACT
SENTIMENT
XAIR : Nasdaq
Beyond Air® Presents In Vivo Solid Tumor Data Confirming In Situ Cancer Vaccination with a Single Injection of Gaseous Nitric Oxide at the AACR Conference on Tumor Immunology and Immunotherapy
Stock XAIR logo
Beyond Air Inc

Nasdaq:XAIR

XAIR Rankings

#5851 Ranked by Market Cap
#5085 Ranked by Stock Gains
N/A Ranked by Dividends

XAIR Stock Data

Other Industrial Machinery Manufacturing
Manufacturing
Link
US
Garden City

About XAIR

Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company developing a revolutionary NO Generator and Delivery System, LungFit™, that uses NO generated from ambient air to deliver precise amounts of NO to the lungs of ventilated and non-ventilated patients for the potential treatment of a variety of pulmonary diseases. LungFit™ can generate up to 400 ppm of NO for delivery either continuously or for a fixed amount of time, and has the ability to either titrate dose on demand or maintain a constant dose. The Company is currently applying its therapeutic expertise to develop treatments for pulmonary hypertension in various settings, in addition to treatments for respiratory tract infections that are not effectively addressed with current standards of care. Beyond Air is currently advancing its innovative LungFit™ in clinical trials for the treatment of severe lung infections such as SARS-CoV-2 and nontuberculous mycobacteria (NTM). Additionally, Beyond Air is performing preclinical testing of the use of ultra-high concentrations of NO with a proprietary delivery system, separate from LungFit™, to target certain solid tumors.